Four reasons patients come, and one section on why we sometimes tell them not to. If a page only lists advantages, it is selling you something.
Regulatory timelines differ. Several CAR-T products licensed in China are not licensed elsewhere, or are licensed for fewer indications. Hundreds of trials recruiting in China are not open to non-residents elsewhere. For a patient who has exhausted approved options, this is often the entire reason for travelling.
We schedule directly with the department rather than through a referral queue. Where a public system might take months to reach a specialist appointment, we are typically confirming dates within weeks.
The busiest tertiary centres in China handle case loads that Western centres rarely see. In surgery and in haematopathology, repetition is the variable that correlates most reliably with outcomes.
Typically 45–70% below comparable US pricing for the same class of treatment, and you receive a written estimate before committing to anything.
| Treatment | US | China | Difference |
|---|---|---|---|
| CAR-T therapy (licensed product) | $373,000 – $475,000 | $137,000 – $165,000 | ~60–65% |
| CAR-T via clinical trial | $373,000+ | $40,000 – $80,000 | ~80% |
| Complex surgery | $80,000 – $150,000 | $25,000 – $50,000 | ~60% |
| Full-arch dental restoration | $20,000 – $35,000 | $7,000 – $13,000 | ~60% |
Illustrative, based on published pricing. Not a quotation. Hospitalisation, monitoring, medication and complications can change the total materially.
We turn away a meaningful number of enquiries, and we do it at the free stage. The common reasons:
No commitment, no fee. If China is not the right answer for your case, we will tell you that first.
What to send: diagnosis, most recent pathology report, treatment history, and latest imaging. Reply within 48 hours.
